Richter Gedeon of Hungary has reported a 37.3% climb in net profits to12.04 billion forint ($42.6 million) for the six months ended June 30, while sales increased 30.3% to 44.71 billion forint. Domestic turnover rose 28.4% to 12.29 billion forint, and the company noted that exports reached $111.1 million, a rise of 20.9%.
Richter said that the rise in domestic revenues is partly the result of stockpiling by wholesalers and pharmacies ahead of 6.3% price increases as of July 1. The company added that the recently-signed pricing agreement with the Hungarian government "has also made possible that new products should come to the market in the coming months." These are expected to include antidepressants, anti-inflammatory fungicide products and hormone supplements.
In the Commonwealth of Independent States, Richter's sales amounted to $43.4 million, a 29.9% rise driven by a 52% increase in revenues from oral contraceptives. In Russia alone, sales amounted to $32.4 million, according to a Reuters report.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze